Shinichi Oka

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 593 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +10

Adaptation of HIV-1 to human leukocyte antigen class I

Yuka Kawashima, Katja Pfafferott, John Frater et al. · Nature · 2009 · 464 citations · Full text

Primary Immunodeficiency, Human Retrovirus, Immunology +4

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 427 citations · Full text

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens

K. Tsuchiya, Hiroyuki Gatanaga, Natsuo Tachikawa et al. · Biochemical and Biophysical Research Communications · 2004 · 272 citations

Viral Persistence, Human Retrovirus, Immunology +8

Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26

Hiroyuki Gatanaga, Tsunefusa Hayashida, K. Tsuchiya et al. · Clinical Infectious Diseases · 2007 · 222 citations